Does maternal immunization blunt the effectiveness of pertussis vaccines in infants? Too early to tell

Michael Briga[a], Elizabeth Goult[a], Tobias S Brett[b,c], Pejman Rohani[b,c], Matthieu Domenech de Cellès[a]

[a]Infectious Disease Epidemiology Group, Max Planck Institute for Infection Biology, Berlin, Germany

[b]Odum School of Ecology, University of Georgia, Athens, GA 30602

[c]Center of Ecology of Infectious Diseases, Athens, GA 30602

Abstract

Pertussis, a highly contagious respiratory infection primarily caused by the bacterium *Bordetella pertussis*, remains a public health priority largely because of the persistently high disease burden in infants too young to be vaccinated. To protect this vulnerable demographic, maternal immunization during pregnancy has been adopted in an increasing number of countries over the last decade. Although this strategy is effective at protecting unvaccinated newborns, it has been demonstrated to cause immunological blunting, whereby maternal antibodies reduce the infant's immune response to pertussis vaccines. However, the clinical and epidemiological consequences of immunological blunting remain unclear. To illuminate these consequences, we first reviewed the epidemiological evidence for the blunting of vaccine effectiveness after primary immunization of infants. Of the four studies identified, all had short-time monitoring (range: 2–6 years), and their results were heterogeneous, with some estimates consistent with blunting. Next, to better interpret this epidemiological evidence, we extended a previously validated model of pertussis transmission by incorporating maternal immunization with varying degrees of blunting, assumed to reduce the vaccine effectiveness in infants born to vaccinated mothers. Our simulations show three results. First, we find evidence for a transient phase lasting at least a decade after the start of maternal immunization, during which the long-term epidemiological impact of blunting is masked. Hence, ignoring these transient dynamics results in an overestimation of the effectiveness of maternal immunization. Second, because of this transient effect, we show that current empirical estimates may be consistent with a modest level of blunting, amounting to a 10–20% reduction in vaccine effectiveness. However, the large between-study heterogeneity and within-study statistical uncertainty preclude a definitive conclusion, urging for more research to infer the degree of blunting, if any. Ultimately, we predict that, regardless of the degree of blunting, maternal immunization remains effective at reducing pertussis in unvaccinated newborns, supporting the continued use of this strategy to protect this vulnerable population. More generally, our results suggest that maternal immunization can result in an infection-control trade-off between age groups, of practical relevance to many other vaccine-preventable diseases.

Introduction

Pertussis is a highly transmissible respiratory infection that is primarily caused by the bacterium *Bordetella pertussis* [1,2]. Pertussis was a leading cause of childhood mortality until intense immunization programs starting from the 1940s onwards, reduced pertussis notifications by over 90% in many countries [3]. However, in the last couple of decades, pertussis has re-emerged in many populations with high long-term immunization coverage, for reasons which remain highly debated [4].

Newborns are the demographic most vulnerable to pertussis. In high-income countries, pertussis-related hospitalization rates in infants under 6 months are between 100 and 100,000 per year [5], and data from the US [6] and Australia [7] show that over 60% of pertussis-associated hospitalizations are under one year old. To reduce the burden of pertussis in vulnerable newborns, many countries have recently introduced maternal immunization—*i.e.*, vaccinating pregnant individuals, usually during the second or third trimester of pregnancy, with a low-dose tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine. In 2015, the World Health Organization (WHO) issued an official recommendation for maternal immunization against pertussis [8], and by 2020 maternal immunization against pertussis was recommended in 55 countries [9].

Maternal immunization is highly effective at protecting newborns, with estimates of reductions in pertussis incidence ranging from 70 to 95% [10–14]. However, the downstream consequences of maternal immunization, when infants receive their routine pertussis vaccines, are not well understood. Specifically, there has been long-standing concern regarding potential immunological blunting, *i.e.*, the interference of maternally-transferred antibodies with the infant immune response [15,16]. Indeed, several studies and meta-analyses have shown that, after infants received their primary immunization, the antibody concentrations against several pertussis antigens were reduced by 25%–50% in infants from vaccinated mothers relative to infants from unvaccinated mothers [17–19]. Similarly, the avidity of pertussis antibodies is reduced in infants from vaccinated mothers [20]. Interestingly, the blunting response following maternal pertussis immunization appears to be heterologous, also causing decreased antibody concentration after infants received a polio vaccine [21] and the blunting response also

applies to other vaccines that contain (modified) diphtheria or tetanus toxins as carrier proteins, such as pneumococcus conjugate vaccines and *Haemophilus influenzae* type b vaccine [21].

While immunological blunting is well documented, because maternal immunization was implemented only recently, the consequences of blunting on vaccine effectiveness and the ensuing epidemiology of pertussis remain poorly evaluated. Especially, the recent rollout of maternal immunization and associated short-term epidemiological data make it difficult to detect long-term transmission impacts. Here, we assess the epidemiological evidence for blunting, which we interpret in two steps. First, we review the epidemiological literature for estimates of the impact of maternal immunization on the risk of contracting pertussis after the infant's primary pertussis immunization, which usually consists of two or three vaccine doses given between the ages of two or three months until six months (Table S1, [22]). Second, we extend a previously validated model of pertussis immunization [3,23] to simulate the *long-term* epidemiological impact of maternal immunization with various levels of blunted protection and maternal immunization coverages on the age-specific time series of pertussis incidence. Our study shows that following the implementation of maternal immunization, there is a transient "honeymoon" phase lasting at least a decade [24]. Ignoring these transient dynamics, as is the current practice in empirical studies, results in an overestimation of the effectiveness of maternal immunization. Comparing our model predictions with the results of epidemiological studies, we find that the available empirical estimates, though largely heterogeneous, may be consistent with a modest (10–20%) blunting of vaccine effectiveness in infants born to vaccinated mothers. Even so, we predict that maternal immunization remains effective at reducing pertussis in unvaccinated newborns. Hence, our results support the continued use of maternal immunization to protect this vulnerable population but highlight a potential infection-control trade-off associated with this strategy.

Methods

Literature search for empirical studies on the relative risk of contracting after maternal immunization

To search the literature, we started with the first two studies that estimated maternal immunization effectiveness on pertussis incidence among children who received at least one dose of primary immunization [11,12] and went through all peer-reviewed studies citing these articles using Google Scholar on August 26, 2022 (Fig. 1). To be included in our overview, studies had to provide an estimate of the effectiveness of maternal immunization or of the relative risk (RR) of contracting pertussis in infants having received their primary series of pertussis vaccines from vaccinated vs. unvaccinated mothers.

Simulation: Model schematic

We implemented an age-structured model of pertussis transmission, extending a previous model empirically validated on data from Massachusetts, USA [3]. In brief, the model is based on the Susceptible-Exposed-Infected-Recovery (SEIR, Fig. S1) model in which pertussis vaccines can fail by (i) failure in "take" (primary vaccine failure) and (ii) failure in duration (waning of vaccine protection) [25]. Based on immunological evidence showing an immediate reduction in the antibody response to primary vaccination [17–19], we assumed that blunting from maternal immunization increased the probability of primary vaccine failure. Previous results in [3] found no evidence for failure in degree (or leakiness), and hence we ignored this possibility.

The model is designed such that we follow individuals according to their immunization history (Fig. S1), starting from their mother's immunization status during pregnancy, followed by an infant immunization schedule that resembles that of the empirical studies in Table S1: the infant's primary immunization occurs at the age of three months and an infant booster at the age of 1.5 years. Newborns can be born in three possible compartments: from vaccinated mothers whose immunization succeeded, mothers whose immunization failed, or unvaccinated mothers. Each of these compartments is followed by a compartment for successful primary infant immunization (Fig. S1) and a compartment for failed primary infant immunization, thereby becoming susceptible (Fig. S1). Following the first booster, these susceptibles become immunized again at an

effectiveness of 96%, with a subsequent waning rate of vaccine protection of 0.011 yr^{-1} (Table S3).

Model parametrization

Our model is based on [3], which was fitted to pertussis incidence data from Massachusetts to identify the model parameters that best characterized the data. Hence, for the parameters consistent between both models, we used the estimates from ([3], Table S3).

By adding maternal immunization to this model, we also added three new parameters. The first parameter is maternal immunization coverage, for which empirical studies showed a range between 50% and 90% (Table S1). The second parameter is the duration of maternally derived immunity, for which, to the best of our knowledge, there are no empirical estimates. One proxy is the half-life of maternal antibodies, which ranges between 29 and 36 days [26,27], suggesting that the duration of maternally-derived immunity is short. However, because of the absence of definite correlates of protection [28–30], the correspondence between the waning rate of maternal antibodies and that of maternal immunity is unknown. For example, if both waning rates are assumed equal, according to our model the effectiveness of maternal immunization in the first two months after birth would be close to 50% (Fig. S1). This is in contrast with the estimated effectiveness of maternal immunization in that age class, which ranged from 78% (95% CI: 48–90; [13]) to 93% (95% CI: 81–97, [10]). Thus, in our model, we calibrated the average duration of maternal protection to reach these empirical estimates of vaccine effectiveness. Here we show results with an average duration of 8.7 months (Table S3, Fig. S2), with variation in the average durations ranging from 4 months to 12 months (Fig. S7, Fig S8). The third parameter is the blunting of infant immune protection, defined as the relative reduction in the effectiveness of the primary series in infants born to vaccinated mothers (compared to infants born to unvaccinated mothers). In simulations, we considered blunting levels ranging from 0% (no blunting) to 20%.

Estimation of relative risk of infection following maternal immunization

To connect the model outputs with the empirical estimates of relative risk (RR) [11,12,14,31], we calculated the risk of contracting pertussis in infants born to vaccinated mothers relative to that of infants born to unvaccinated mothers using the same approach as in [11,31]. These studies used the screening method following [32], in which the RR is estimated as:

$$RR = \frac{PCV}{(1 - PCV)} \cdot \frac{(1 - PPV)}{PPV}$$

where PCV is the proportion of cases in infants vaccinated born to vaccinated mothers (among all cases in infants vaccinated) and PPV the proportion of mothers vaccinated (maternal immunization coverage). The RR is a number greater than or equal to zero, with (i) 0 indicating no infections in infants of vaccinated mothers and hence a 100% effectiveness of maternal immunization, (ii) a value of 1 reflecting that infants from vaccinated and unvaccinated mothers have an equal risk of contracting pertussis, hence maternal vaccination having no effect on the protection against pertussis in infants, and (iii) a value above 1 indicating that infants from vaccinated mothers have an increased risk of contracting pertussis relative to infants from unvaccinated mothers. We validated the RR estimates of the simulations by setting the half-life of maternally derived protection to infinity, which resulted in 5% RR in newborns (Fig. S2), matching the initial 95% effectiveness of maternal immunization against pertussis in unvaccinated newborns fixed in the simulations (Table S3). Hence, while the screening method may have several limitations in real-world settings [33], it provided reliable estimates of vaccine effectiveness in the context of our model.

Numerical implementation

We represented the process model as a continuous-time Markov process, approximated via the tau-leap algorithm [34] with a fixed time step of 1 day. To compare the model outputs to empirical estimates, we also added an observation model for the RR. This was done by sampling the number of vaccinated cases born to vaccinated mothers from a Binomial distribution with probability PCV and size equal to the sample size of each empirical study. The model was implemented and simulated using the 'pomp' package v. 4.4.3.0 [35], operating in R v. 4.2.0 [36].

Results

Empirical estimates

We identified 276 articles and, after removing 44 duplicate records, screened 232 abstracts (Fig. 1). Our search resulted in five estimates from four studies, with two studies carried out in the UK, one in Australia, and one in California, US (Fig. 2, Table S1). In all studies, maternal immunization coverage was low right after the implementation of maternal immunization but increased to reach >80% (mean: 83%; range: 80%–87%) within two to six years (Table S1). These studies showed that the protective effect of maternal immunization decreased with increasing doses during the infants' primary immunization (Table S1). After the first dose, the RR was low at an average of 0.3, ranging from 0.2 (range of 95% CI lower bounds: 0.1–0.4) to 0.7 (range of 95% CI upper bounds: 0.3–1.8; Fig. 2). After the second or third dose of infant primary immunization, the average RR was 1, with estimates ranging from 0.3 (95% CI: 0.1–0.95) to 1.2 (95% CI: 0.3–2.9; Fig. 2).

The model recapitulates the historical trends of pertussis, with a resurgence caused by a honeymoon effect

To assess the historical impact of routine immunization in infants, we first examined the trends in overall incidence and age-specific susceptibility. Infant immunization induced a strong decrease in pertussis incidence but was followed by a rebound with a gradual buildup of susceptible individuals in adult age groups until a new equilibrium—with lower incidence than in the pre-vaccine era—was reached several decades later (Fig. 3 A & B). As we previously demonstrated in the US, this resurgence was explained as an "end-of-honeymoon" effect, a predictable consequence of incomplete immunization with imperfect but highly effective vaccines. Hence, our model recapitulated the historical dynamics of pertussis in the US, characterized by a resurgence and shift of infections to adolescent and adult age groups [3].

Transient dynamics after the start of maternal immunization

238 Second, we examined the impact of maternal immunization, which we introduced 100
239 years after the rollout of infant immunization, to disentangle the consequences of the two
240 immunization programs. Maternal immunization had the intended effect of decreasing
241 susceptibility to infection in unvaccinated newborns aged 0–2 mo (Fig. 3B). However,
242 after the start of maternal immunization, the model predicted a transient phase with
243 lower pertussis incidence, lasting at least 5 years and followed by a rebound (Fig. 4A). In
244 newborns, the predicted incidence of pertussis was higher in a scenario with blunting
245 relative to without blunting, but it always remained lower than before the start of
246 maternal immunization (Fig. 4A). Thus, maternal immunization was predicted to be
247 effective at protecting unvaccinated newborns, with benefits by far outweighing any
248 possible blunting-mediated increases in incidence.
249
250 By contrast, in the second age class of infants aged 3–18 mo, (i.e, after receipt of the
251 primary pertussis immunization), maternal immunization was followed by a decrease of
252 pertussis incidence, but only when blunting was low (<10%, Fig. 4B). At higher levels of
253 blunting, pertussis incidence was predicted to increase relative to before the start of
254 maternal immunization (Fig. 4B). However, the second age class also showed a clear
255 transient phase, lasting at least 5 years. During this transient phase, pertussis incidence
256 was first predominantly driven by infants from unvaccinated mothers (Fig. 4C), followed
257 later on by incidence in infants from vaccinated mothers, who dominated once incidence
258 had reached equilibrium (Fig. 4D). These dynamics persisted in children up to 5 years of
259 age, but dissipated by age 10 years, after which pertussis incidence remained low and the
260 effects of both maternal immunization and blunting on pertussis incidence were
261 negligible (Fig. S3).
262
263 *Comparison with empirical estimates suggests that blunting cannot be ruled out*
264
265 Lastly, we estimated the impact of blunting on the RR of pertussis in vaccinated infants
266 born to mothers vaccinated during pregnancy. In newborns, our simulations show that
267 estimates of the effectiveness of maternal immunization (*i.e.*, based on incidence) have a
268 transient phase in a direction consistent with those deduced from the transient incidence
269 dynamics: the effectiveness was high at first but decreased with time, and equilibrium
270 values were reached only after a transient phase that lasted at least a decade (Fig. 5A).

271 Hence, ignoring the transient dynamics results in an overestimation of the effectiveness
272 of maternal immunization, an effect most pronounced during the first decade after
273 implementation.
274
275 As expected, in the second age class of infants aged 3–18 mo, (*i.e.*, after receipt of the
276 primary pertussis immunization), blunting resulted in RR equilibrium values above 1 (*i.e.*,
277 a higher risk of pertussis in infants born to vaccinated mothers), which increased with
278 the input blunting strength. However, these risks were reached only after a transient
279 phase that lasted more than a decade (Fig. 5B). During this transient phase, even in
280 scenarios with blunting, the RR was initially far below 1 and gradually increased after the
281 start of maternal immunization. Hence, ignoring these transient dynamics and assuming
282 that a RR of 1 indicates no blunting may result in overestimating the effectiveness of
283 maternal immunization in both unvaccinated newborns and vaccinated infants (Fig. 5B).
284 It is noteworthy that the transient phase for the estimation of RR or vaccine effectiveness
285 (Fig. 5 A & B) is longer than for the incidence (Fig. 4 A & B). This is because RR and VE are
286 cumulative estimates instead of instantaneous estimates such as incidence (Fig. S4).
287 Interestingly, depending on the contact matrix, the incidence during the transient phase
288 showed oscillating dynamics, which increases the variability between estimates that are
289 done after 3, 6, or even 10 years (Figs. S12, S13), but these oscillations disappeared in the
290 RR estimates (Figs. S14, S15), likely thanks to their cumulative nature. Interestingly, after
291 the transient phase, a scenario without blunting resulted in RRs below one, due to
292 residual protection from maternal antibodies in infants who were vaccinated but in
293 whom the vaccine did not take. This result suggests that the usual assumption that a RR
294 of 1 indicates no blunting may be too optimistic.
295
296 Comparing our model predictions with the results of epidemiological studies, all current
297 empirical RR estimates fell well within the transient phase of our simulations (Fig. 5C).
298 Demographic stochasticity accounted for some of the variability in the predicted RR (Fig.
299 5B), but observation noise due to small sample sizes was by far the largest source of
300 uncertainty (Fig. 5C). Inspecting the overlap between confidence intervals, all the
301 empirical estimates were consistent with blunting, even though two estimates (in the UK
302 and California) were also consistent with no blunting. Hence, according to our
303 simulations, current empirical studies cannot yet detect the eventual epidemiological

consequences of blunting (Fig. 5B), and the model-data comparison suggests that a modest level of blunting cannot be ruled out (Fig. 5C).

Sensitivity analysis

We checked the sensitivity of our results to variations in five parameters: (i) maternal immunization coverage, ranging from 50% to 90% (Fig. S5, S6); (ii) average duration of maternal protection, ranging from 4 months to 1 year (Fig. S7, S8); (iii) beginning primary immunization at 2, 4 and 9 months (Fig. S9, S10); (iv) different social contact matrices from 8 European countries, as described in the surveys by [37,38] (Fig. S11-S16); and (v) with the maternal immunization program starting 60 years after the infant immunization program, as was the case in many countries (Fig. S17, S18). In our simulations, variation in these parameters had a substantial impact on pertussis incidence but did not affect the temporal dynamics in RR following maternal immunization (Fig. S5-S18). Another noteworthy result was that a considerable reduction of the blunting effect was predicted when delaying the age at the start of the infant's primary immunization by a few months (Fig. S9, S10). Hence, our main results were, on the whole, robust to assumptions about fixed model parameters.

Discussion

In this study, we aimed to review the epidemiological evidence about the impact of maternal immunization on the effectiveness of pertussis vaccines in infants and to interpret this evidence using a new mechanistic mathematical model that represented the effect of blunting on pertussis transmission dynamics. Our review identified four observational epidemiological studies, all of which had short monitoring times and often combined with small sample sizes. Most studies suggested a reduced risk of pertussis after receipt of the first vaccine dose in infants born to mothers immunized during pregnancy. After receipt of the second or third vaccine dose, however, the estimates were more heterogeneous and, due to high estimate uncertainty, consistent with a range of assumptions about the impact of maternal immunization. To interpret these empirical estimates, we performed a simulation study using an age-structured model of pertussis transmission. This model predicted that the introduction of maternal immunization was

337 followed by a transient phase lasting at least a decade, during which the blunting effect
338 of maternal antibodies could be underestimated. The model-data comparison suggested
339 that a modest level of blunting could not be ruled out, even though the large uncertainty
340 in empirical estimates prevented a definitive conclusion. Even in the presence of such
341 blunting, however, our model predicted that maternal immunization remained effective
342 at reducing pertussis in unvaccinated newborns. Hence, our results confirm that maternal
343 immunization is an effective strategy to protect this age group, but suggest it may
344 eventually result in an infection-control trade-off with older age groups.
345
346 Unvaccinated newborns are the demographic most vulnerable to pertussis, both in terms
347 of infection and hospitalization risks [5],[6],[7]. Our study suggests that, although
348 maternal blunting may erode the benefits of immunization in infants, it is highly effective
349 at protecting unvaccinated newborns. Hence, our results support the decision of many
350 public health authorities to introduce maternal immunization against pertussis, provided
351 that the main control objective is to protect newborns [8,9]. More generally, given the
352 vulnerability of newborns to many pathogens, maternal immunization against other
353 infectious diseases is considered by public health authorities and the pharmaceutical
354 industry. For example, a new maternal vaccine against RSV recently underwent a
355 successful phase 2b trial [39]. Aside from pertussis, blunting of infant antibody
356 concentration following maternal immunization has been demonstrated for many
357 infections, including diphtheria, tetanus, pneumococcus, meningococcus, tuberculosis,
358 polio, measles, mumps, and rotavirus [15,17,40,41]. Maternal immunization, therefore,
359 also appears as a promising strategy to protect newborns against these infections, but
360 our results suggest the need to monitor its impact on subsequent vaccination of infants
361 carefully.
362
363 One of the main takeaways from our review was the large heterogeneity and uncertainty
364 of available empirical estimates, emphasizing the urgent need for more research on
365 maternal blunting. However, if such blunting is confirmed by future evidence, there are
366 ways to mitigate its impact. Immunity in newborns conferred by maternal antibodies
367 against pertussis likely wanes quickly, on a timescale of months according to our model.
368 Given these fast waning rates, delaying infant primary immunization by a few months
369 might greatly reduce the maternal blunting of infant immunization [17]. Pertussis

370 immunization schedules vary greatly between countries, with the age at first
371 immunization of infants typically ranging between two and four months [22], and the
372 current variation in pertussis immunization schedule can significantly impact the
373 effectiveness of pertussis immunization in infants [42]. If maternal blunting occurs, our
374 results suggest that the optimal age at first immunization is governed by a trade-off
375 between vaccinating too early (with the effect of reducing the susceptibility age window
376 in newborns but amplifying the impact of blunting in vaccinated infants) and too late
377 (with the opposite effect). As the costs of infection in unvaccinated newborns likely
378 exceed those in older age groups, the introduction of maternal immunization may thus
379 increase the optimal age at first immunization, in all infants or only in those born to
380 vaccinated mothers. Interestingly, the Dutch public health authorities take a distinct
381 approach: children from unvaccinated mothers get their first pertussis immunization at
382 the age of two months, while children from vaccinated mothers get their first dose at
383 three months [43]. Identifying the optimal pertussis immunization schedule for infants
384 would be helpful for public health authorities, especially given the vast between-country
385 variation in pertussis immunization schedules [22,42,44]. Our new model could thus help
386 future research on optimal vaccine schedules.
387
388 After the roll-out of maternal immunization, our model predicted a transient phase
389 lasting approximately a decade, during which the incidence of pertussis—in both
390 unvaccinated newborns and vaccinated infants—initially dropped, but then bounced
391 back and re-increased to reach a new equilibrium. The duration of this transient phase is
392 consistent with that found in a previous modeling study [45] and may be explained by
393 the time required for the first cohorts of blunted-vaccinated infants (*i.e.*, born to
394 vaccinated mothers) to reach primary school age and its associated high contacts. Hence,
395 reduced transmission from unvaccinated newborns may explain the initial decrease in
396 incidence across age groups, but this benefit gradually wears off as blunted-vaccinated,
397 and therefore less well-protected, children age.
398
399 From a practical perspective, this transient phase has at least two important implications.
400 First, the current epidemiological studies had ≤6 years of monitoring, a time frame we
401 predict is insufficient to capture the long-term consequences of maternal immunization.
402 Second, a RR of 1 is considered the baseline value indicating that maternal immunization

403 does not blunt vaccine effectiveness in infants. In the transient phase, however, our model
404 predicts that the baseline value under a no-blunting scenario starts off close to 0 and
405 gradually increases to an equilibrium just below 1. This equilibrium value results from
406 the residual protection from maternal antibodies, which partially compensates for
407 failures of primary immunization in infants born to vaccinated mothers. These results
408 suggest that the early empirical estimates of vaccine effectiveness may overestimate the
409 benefits of maternal immunization, both for newborns and for infants. A testable
410 prediction of our model, therefore, is that the benefits of maternal immunization
411 estimated in subsequent studies will be lower than those currently reported, both in
412 newborns and after the primary series. Note though that the COVID-19 pandemic and its
413 associated lockdown will have changed the temporal dynamics of RR following maternal
414 immunization. More broadly, as reflected in some official guidelines for vaccine impact
415 evaluation [46] and demonstrated for other vaccines such as influenza and
416 streptococcus, biased estimation of vaccine effectiveness because of transient dynamics
417 early after vaccine roll-out is likely a more general occurrence.
418
419 In addition to the monitoring time, other components of the design of current
420 epidemiological studies may affect their interpretation. First, as the mothers' decision to
421 receive Tdap during pregnancy is voluntary and likely related to other socioeconomic
422 status factors that will affect—and presumably reduce—their infants' risk of pertussis,
423 the baseline comparability between groups is far from obvious in these observational
424 studies. Hence, estimates of the effectiveness of maternal immunization may have been
425 confounded by healthy user bias; interestingly, the only study that controlled for most
426 characteristics of the mothers [14] had large statistical uncertainty and could not rule out
427 blunting. In addition to this confounding problem, maternal immunization may prevent
428 mothers from transmitting pertussis to their infants, an indirect effect that could lead to
429 underestimating the risk of pertussis and masking the effect of blunting in the group of
430 infants vaccinated and born to vaccinated mothers (as recognized by some
431 investigators [11]). Because of these potential biases, current RR estimates may have
432 been underestimated, and our model predictions regarding the level of blunting may be
433 conservative.
434

Our study has several limitations. First, our model was parameterized based on previous estimates in Massachusetts, USA, and may only correctly represent pertussis epidemiology in comparable high-income countries. Second, in the absence of serological correlates of protection for pertussis [28–30], the duration of maternally-derived protection—and in particular how it connects to maternal antibody titers in the infant—is unknown. In our model, this parameter was calibrated to reach empirical estimates of maternal immunization effectiveness in newborns, with an average duration of maternally derived protection at 8.7 months resulting in vaccine effectiveness for newborns close to 80%. Even though sensitivity analyses demonstrated that our main results were robust to variations in this parameter, more accurate estimation will be important to inform future models and predict optimal vaccination schedules. Third, for simplicity, we did not model the direct, protective effect of maternal immunization on mothers—only the indirect effect on their newborns. This direct effect is an additional benefit of maternal immunization, but because in high-income countries the proportion of women giving birth is small relative to the total adult population, it is expected to have a minor epidemiological impact. Fourth, in our simulations, maternal immunization coverage was fixed at 70%, while in real-world settings it is often initially low and gradually increases. However, such temporal variations in immunization coverage are expected to increase the duration of the transient phase and would thus reinforce our conclusions about the unreliability of early empirical estimates.

To conclude, our study shows that maternal immunization is effective at protecting newborns, even when blunting erodes some of its benefits. The degree of blunting, and the extent to which it entails an epidemiological cost in older age groups, can not be known yet, as we predict that the implementation of maternal immunization is followed by a transient phase during which the epidemiological impact of blunting is masked. Hence, current epidemiological studies may be insufficient to rule out blunting or grasp the long-term epidemiological consequences of maternal immunization. Our results, therefore, identify the need for more research to precisely estimate the degree of blunting after primary immunization, if any. More generally, our study supports the use of maternal immunization to reduce pertussis in newborns, but suggests this strategy may be associated with an infection-control trade-off between different age groups.

467 **References**

468 1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease,
469 Treatment, and Prevention. Clin Microbiol Rev. 2016;29: 449–486.

470 2. Rohani P, Scarpino SV, editors. Pertussis: Epidemiology, Immunology & Evolution.
471 Oxford University Press, Oxford; 2019.

472 3. Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The impact of past
473 vaccination coverage and immunity on pertussis resurgence. Sci Transl Med.
474 2018;10: eaaj1748.

475 4. Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The pertussis enigma:
476 reconciling epidemiology, immunology and evolution. Proc Biol Sci B. 2016;283:
477 20152309.

478 5. Kandeil W, van den Ende C, Bunge EM, Jenkins VA, Ceregido MA, Guignard A. A
479 systematic review of the burden of pertussis disease in infants and the effectiveness
480 of maternal immunization against pertussis. Expert Rev Vaccines. 2020;19: 621–
481 638.

482 6. Mbayei SA, Faulkner A, Miner C, Edge K, Cruz V, Peña SA, et al. Severe Pertussis
483 Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69: 218–226.

484 7. Quinn HE, Comeau JL, S MH, J EE, W CN, Blyth CC, et al. Pertussis disease and
485 antenatal vaccine effectiveness in Australian children. Pediatr Infect Dis J. 2022;41:
486 180–185.

487 8. World Health Organization. Pertussis vaccines: WHO position paper – August 2015.

488 9. Abu-Raya B, Maertens K, Edwards KM, Omer SB, Englund JA, Flanagan KL, et al.
489 Global perspectives on immunization during pregnancy and priorities for future
490 research and development: an international consensus statement. Front Immunol.
491 2020;11: 1282.

492 10. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro E Sonia Kara, Fry NK,
493 et al. A case-control study to estimate the effectiveness of maternal pertussis
494 vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin
495 Infect Dis. 2015;60: 333–337.

496 11. Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Sustained
497 effectiveness of the maternal pertussis immunization program in England 3 years
498 following introduction. Clin Infect Dis. 2016;63: S236–S243.

499 12. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of vaccination
500 during pregnancy to prevent infant pertussis. Pediatrics. 2017;139: e20164091.

501 13. Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, et al. Impact of
502 the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program
503 on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation.
504 Clin Infect Dis. 2017;65: 1977–1983.

505 14. Rowe SL, Leder K, Perrett KP, Romero N, Nolan TM, Stephens N, et al. Maternal
506 vaccination and infant influenza and pertussis. Pediatrics. 2021;148: e2021051076.

507 15. Albrecht P, A EF, Saltzman EJ, S K. Persistence of maternal antibody in infants
508 beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977;91: 715–
509 717.

510 16. Bento AI, King AA, Rohani P. Maternal pertussis immunisation: clinical gains and
511 epidemiological legacy. Euro Surveill. 2017;22: 30510.

512 17. Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O'Brien KL, Perera R, et al. The
513 influence of maternally derived antibody and infant age at vaccination on infant
514 vaccine responses: an individual participant meta-analysis. JAMA Pediatr. 2017;17:
515 637–646.

516 18. Barug D, Pronk P, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, et al.
517 Maternal pertussis vaccination and its effects on the immune response of infants
518 aged up to 12 months in the Netherlands: an open-label, parallel, randomised
519 controlled trial. Lancet Infect Dis. 2019;19: 392–401.

520 19. Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, et al.
521 The effect of Tetanus-Diphtheria-Acellular-Pertussis immunization during
522 pregnancy on infant antibody responses: individual-participant data meta-analysis.
523 Front Immunol. 2021;12: 689394.

524 20. Caboré RN, Maertens K, Dobly A, Leuridan E, Van Damme P, Huygen K. Influence of
525 maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of
526 infant antibody responses to a pertussis containing vaccine in Belgium. Virulence.
527 2017;8: 1245–1254.

528 21. Zimmermann P, Perrett KP, L MN, Donath S, Ritz N, van der Klis FRM, et al. The
529 effect of maternal immunisation during pregnancy on infant vaccine responses.
530 EClinicalMedicine. 2019;13: 21–30.

531 22. Perkins TA, Tran QM. Timing is everything when it comes to pertussis vaccination.
532 Lancet Infect Dis. 2022;22: 158–159.

533 23. Domenech de Cellès M, Rohani P, King AA. Duration of Immunity and Effectiveness
534 of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. JAMA Pediatr.
535 2019;173: 588–594.

536 24. McLean AR, Anderson RM. Measles in developing countries Part I. Epidemiological
537 parameters and patterns. Epidemiol Infect. 1988;100: 111–133.

538 25. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc B
539 Biol Sci. 1993;253: 9–13.

540 26. Healy CM, Rench MA, Swaim LS, Timmins A, Vyas A, Sangi-Haghpeykar H, et al.
541 Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated
542 with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy. Vaccine.
543 2020;38: 5955–5961.

27. Oguti B, Ali A, Andrews N, Barug D, Anh Dang D, Halperin SA, et al. The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2022;40: 450–458.

28. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24: S62–S65.

29. Diavatopoulos DA, Mills KHG, Kester KE, Kampmann B, Silerova M, Heininger U, et al. PERISCOPE: road towards effective control of pertussis. Lancet Infect Dis. 2019;19: e179–e186.

30. Chen Z, Liu X, Zhang Y, Peng X, Zhang N, Chen N, et al. Evaluation of serum anti-pertussis toxin IgA antibodies for the diagnosis of Bordetella pertussis infection in young children. J Infect Public Health. 2023;16: 1167–1173.

31. Amirthalingam G, Campbell H, Ribeiro S, Stowe J, Tessier E, Litt D, et al. Optimization of Timing of Maternal Pertussis Immunization From 6 Years of Postimplementation Surveillance Data in England. Clin Infect Dis. 2023;8: e1129–e1139.

32. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22: 742–746.

33. Minodier L, Blanchon T, Souty C, Turbelin C, Leccia F, Varesi L, et al. Influenza vaccine effectiveness: best practice and current limitations of the screening method and their implications for the clinic. Expert Rev Vaccines. 2014;13: 1039–1048.

34. He D, Ionides EL, King AA. Plug-and-play inference for disease dynamics: measles in large and small populations as a case study. J R Soc Interface. 2010;7: 271–283.

35. King AA, Nguyen D, Ionides EL. Statistical Inference for Partially Observed Markov Processes via the R Package pomp. J Stat Softw. 2016;69: 1–43.

36. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available: https://www.R-project.org/

37. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5: e74.

38. Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases. PLoS One. 2015;10: e0133203.

39. Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein–based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386: 1615–1626.

40. Mawa PA, Nkurunungi G, Egesa M, Webb EL, Smith SG, Kizindo R, et al. The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette–Guérin immunization. Philos Trans R Soc Lond B Biol Sci.

583 2015;3017: 20140137.

584 41. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the
585 Humoral Immune Response to Measles Vaccine in Infants Immunized at Age 6
586 Months. JAMA. 1998;280: 527–532.

587 42. Paireau J, Guillot S, Aït El Belghiti F, Matczak S, Trombert-Paolantoni S, Jacomo V, et
588 al. Impact of vaccine schedule change on pertussis epidemiology in France: a
589 modelling and serological study. Lancet Infect Dis. 2022;22: 265–273.

590 43. Rijksinstituut Voor Volksgezondheid en Milieu. In: Dutch National Immunisation
591 Programme [cited 7 Mar 2023]. Available at:
592 https://rijksvaccinatieprogramma.nl/english

593 44. Riolo MA, Rohani P. Combating pertussis resurgence: One booster vaccination
594 schedule does not fit all. Proc Natl Acad Sci U S A. 2015;112: E472–E477.

595 45. Bento AI, Rohani P. Forecasting Epidemiological Consequences of Maternal
596 Immunization. Clin Infect Dis. 2016;63: S205–S212.

597 46. World Health Organization. Measuring impact of streptococcus pneumoniae and
598 haemophilus influenzae type b conjugate vaccination. 2012. Available at:
599 https://apps.who.int/iris/handle/10665/75835

Acknowledgements

We thank the useful discussions and feedback from Andrew Tredennick (University of Georgia, USA), Christian Gunning (University of Georgia, USA), Denis Macina (Sanofi Pasteur, France), Laurent Coudeville (Sanofi Pasteur, France), and Edward Thommes (Sanofi Pasteur, Canada).

Data Reproducibility

All R scripts are currently available at: https://drive.google.com/drive/folders/1-tT3XaPYwPbviXe1OB7_hvN8SSYe9HYJ, and will be made freely available upon publication via Edmond, the Open Data Repository of the Max Planck Society.

Potential conflict of interests

Prof. Pejman Rohani received funding from Sanofi France for another separate project.



Fig. 1 Prisma flow chart of the literature search for empirical estimates of the relative risk (RR) of contracting pertussis following maternal immunization in children who had received at least one dose of infant primary immunization.



618

619 Fig. 2 Overview of the results from empirical epidemiologic studies of the relative risk of
620 contracting pertussis in infants from vaccinated mothers relative to those of
621 unvaccinated mothers during infant primary immunization. A value of 0 implies complete
622 protection following maternal immunization, and a value of 1 indicates an equal risk of
623 contracting pertussis between infants from vaccinated versus unvaccinated mothers. The
624 literature search protocol is shown in Fig. 1, and the data are available in Table S1. The
625 two lines for the UK 3 years study represent two estimates of maternal immunization
626 coverage. References: Australia 2yrs [14], California 3yrs [12], UK 3yrs [11], and UK 6yrs
627 [31].



Fig. 3 Illustration of honeymoon effects and transient susceptible dynamics following the start of infant immunization (vertical dashed line at time = 0 years) and maternal immunization without blunting (vertical dashed line at time = 100 years) showing (A) pertussis incidence and (B) the fraction susceptible for each age class from one stochastic simulation.



Fig. 4 Model predictions of the consequences of maternal immunization and blunting for pertussis incidence in (A) unvaccinated newborns (aged 0–2 mo) and (B) vaccinated infants (aged 3–18 mo, after receipt of primary immunization). For this age class, during the transient phase after maternal immunization, pertussis incidence is at first mostly driven by (C) infants from unvaccinated mothers until (D) pertussis incidence is most abundant in infants from vaccinated mothers. Panel (D) is consistent with the PCV-term in the RR equation (see methods, [32]). Solid lines show the median incidence of 100 simulations and shaded areas represent the 95% CI. In this figure, all immunization coverages were set at 70%, which is close to the mean observed values in empirical studies (e.g., Table S1). Note the different *y*-axis between panels.


A
0–2 months
Relative risk of pertussis
0.25
0.20
0.15
0.10
1
5
10
25
50
75
Time since start of maternal immunization program (years)
Simulated blunting
0%
10%
20%
B
3–18 months
Relative risk of pertussis
3
2
1
0
1
5
10
25
50
75
Time since start of maternal immunization program (years)
C
3–18 months
Relative risk of pertussis
3
2
1
0
n=20
n=65
n=820
2
3
6
Time since start of maternal immunization program (years)
Study
Australia
California
UK
UK
Simulated blunting
0%
10%
20%

645

646 Fig. 5 Temporal dynamics of the risk of contracting pertussis in (A) unvaccinated
647 newborns and (B, C) vaccinated infants from vaccinated mothers relative to those of
648 unvaccinated mothers. A value of 0 shows 100% protection due to maternal
649 immunization, a value of 1 illustrates an equal risk of contracting pertussis in infants from
650 vaccinated mothers relative to unvaccinated mothers, and any value above 1 shows an
651 increased risk, with for example a value of 2 indicating a two-fold increased risk. (A, B)
652 Solid lines show the median RR of 100 simulations and shaded areas show 95% CI
653 resulting from demographic stochasticity across simulations. (C) Comparison between
654 the results from model simulations (gradient red diamonds) and the empirical studies
655 (colored dots). In simulations, vertical lines show 95% CI due to demographic
656 stochasticity and observation uncertainty, resulting from the partial sampling of the
657 population with sample sizes matching those from empirical studies in Fig. 2 (Table S1).